Metabolite Card
Formula: C26H29NO2 (387.2198)
SMILES: CC\C(=C(/C1=CC=CC=C1)C1=CC=C(OCC[N+](C)(C)[O-])C=C1)C1=CC=CC=C1
Synonyms [en]
tamoxifen N-oxide; (2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}ethyl)dimethylamine oxide; Tamoxifen-N-oxide; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine oxide; (Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine N-Oxide; Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, N-oxide, (Z)-
Last reviewed on 2024-06-28.
Cite this Page
Tamoxifen N-oxide. 数据之源，洞见之始. SMRUCC genomics institute, a synthetic life researcher from China.
https://biocad_registry.innovation.ac.cn/s/(-)-arctiin
(retrieved
2026-01-03) (CAD Registry RN: BioCAD00000018197). Licensed
under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Note
Tamoxifen N-oxide is a metabolite of tamoxifen. Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a mixed agonist/antagonist. Tamoxifen is the usual endocrine therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting. (Wikipedia)
DBLinks
- CAS Registry Number: 75504-34-6
- PubChem CID: 3033895
- ChEBI: 63825
- HMDB: HMDB0060513
- LipidMaps:
- KEGG: C16545
- BioCyc:
- NCBI MeSH: tamoxifen N-oxide
- Wikipedia:
Other DBLinks
- CAS Registry Number: 75504-34-6
- PubChem: 3033895
- ChEBI: ChEBI:63825
- HMDB: HMDB0060513
- KEGG: C16545
- NCBI MeSH: tamoxifen N-oxide
- Metlin: METLIN_710
Class / Ontology
- WishartLab ClassyFire: [Stilbenes] Stilbenes
- ChEBI: [CHEBI:63825] tamoxifen N-oxide
| ID | EC Number | Name |
|---|---|---|
| KEGG:R08266 | 1.14.13.8 | tamoxifen,NADPH:oxygen oxidoreductase (N-oxide-forming) |
Taxonomy Source
Pathway Synthetic
| pathway id | name |
|---|---|
| Reactome:R-BTA-1430728 | Metabolism |
| Reactome:R-BTA-211945 | Phase I - Functionalization of compounds |
| Reactome:R-CEL-211859 | Biological oxidations |
| Reactome:R-CFA-1430728 | Metabolism |
| Reactome:R-HSA-211859 | Biological oxidations |
| Reactome:R-HSA-217271 | FMO oxidises nucleophiles |
| Reactome:R-MMU-1430728 | Metabolism |
| Reactome:R-MMU-211859 | Biological oxidations |
| Reactome:R-MMU-217271 | FMO oxidises nucleophiles |
| Reactome:R-RNO-211945 | Phase I - Functionalization of compounds |
| Reactome:R-SSC-211945 | Phase I - Functionalization of compounds |
| Reactome:R-BTA-211859 | Biological oxidations |
| Reactome:R-BTA-217271 | FMO oxidises nucleophiles |
| Reactome:R-CEL-217271 | FMO oxidises nucleophiles |
| Reactome:R-DRE-211945 | Phase I - Functionalization of compounds |
| Reactome:R-RNO-211859 | Biological oxidations |
| Reactome:R-RNO-217271 | FMO oxidises nucleophiles |
| Reactome:R-SSC-1430728 | Metabolism |
| Reactome:R-SSC-211859 | Biological oxidations |
| Reactome:R-SSC-217271 | FMO oxidises nucleophiles |